Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Res. 2019 Jan 28;79(7):1624–1634. doi: 10.1158/0008-5472.CAN-18-2867

Figure 1. Highly efficient local delivery of immunomodulatory encoded mRNA mediates eradication of the treated tumor.

Figure 1.

12 established A20 tumors were injected with either fluorophore (BDK) or non-fluorophore mRNA-CART. Phenotypic surface marker expression and BDK was used to identify transfected cells (A) Top: Established A20 tumors were injected with non-fluorophore mRNA-CART. Gates indicate background staining. Bottom: Established A20 tumors were injected with (BDK) mRNA-CART. Gates indicates percentage of parent population transfected with mRNA-CARTs. Bar graph: average percent transfected cells in the injected tumor. (B) Expression of immunomodulatory mRNA in HeLa cells 12 hrs after treatment with mRNA-CARTs. (C) Tumor growth and survival of Ctr., CD70, OX40L, CD80/86, IL-12, and IFNγ mRNA-CART treated animals. Mice with tumors >15mm in the largest diameter were euthanized. Survival of OX40L, and CD80 and CD86 mRNA-CART treated mice were compared to control mRNA-CART treated. Survival significance was calculated using Log Rank (Mantel-Cox) test. Ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 ****, P < 0.0001. Data representative of 2–4 independent experiments.